The Use of Risk-Sharing Contracts in Healthcare: Theoretical and Empirical Assessments
- 18 September 2019
- journal article
- review article
- Published by Springer Nature in PharmacoEconomics
- Vol. 37 (12) , 1469-1483
Abstract
Objective The aim of this review is to provide a summary of the literature on risk-sharing agreements, including conceptual, theoretical and empirical (number of agreements and their achievements) perspectives, and stakeholders’ perceptions. Methods We conducted a systematic literature search in MEDLINE from 2000 to April 2019, following PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) methodology, and completed it with a manual search of other publications (mainly grey literature). The search was restricted to publications with English abstracts; the initial identification of articles was restricted to the title, abstract and key words fields. The geographical scope was not restricted. Results Over 20 studies proposed different taxonomies of risk-sharing contracts, which can be summarised as financial and paying-for-performance agreements. Theoretical studies modelling the incentives to implement risk-sharing agreements are scarce; they addressed different types of contracts and regulatory contexts, characterizing the drug prices and the optimal strategies of the involved agents. Empirical studies describing specific agreements are abundant and referred to different geographical contexts; however, few articles showed the economic results and assessed the value of such contracts. Stakeholders’ perceptions of risk-sharing contracting were favourable, but little is known about the economic and clinical advantages of specific agreements. Whether risk-sharing contracts have yielded the desired results for healthcare systems remains uncertain. Conclusion Risk-sharing contracts are increasingly used, although the lack of transparency and aggregated registries makes it difficult to learn from these experiences and assess their impact on healthcare systems.Keywords
Funding Information
- MINECO (ECO2016-78685-R.)
This publication has 59 references indexed in Scilit:
- Performance-Based Risk-Sharing Arrangements—Good Practices for Design, Implementation, and Evaluation: Report of the ISPOR Good Practices for Performance-Based Risk-Sharing Arrangements Task ForceValue in Health, 2013
- The use of risk sharing tools for post adoption surveillance of a non pharmacological technology in routine practice: results after one yearBMC Health Services Research, 2013
- Market access agreements for pharmaceuticals in Europe: diversity of approaches and underlying conceptsBMC Health Services Research, 2011
- What principles should govern the use of managed entry agreements?International Journal of Technology Assessment in Health Care, 2011
- Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payersBMC Health Services Research, 2010
- Access with Evidence Development SchemesPharmacoEconomics, 2010
- Funding the UnfundablePharmacoEconomics, 2010
- Canʼt Get No Satisfaction? Will Pay for Performance Help?PharmacoEconomics, 2010
- The Multiple Sclerosis Risk Sharing Scheme Monitoring Study – early results and lessons for the futureBMC Neurology, 2009
- The views of stakeholders on controlled access schemes for high-cost antirheumatic biological medicines in AustraliaAustralia and New Zealand Health Policy, 2007